BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 22971245)

  • 1. Rational design of DNA vaccines for the induction of human papillomavirus type 16 E6- and E7-specific cytotoxic T-cell responses.
    Oosterhuis K; Aleyd E; Vrijland K; Schumacher TN; Haanen JB
    Hum Gene Ther; 2012 Dec; 23(12):1301-12. PubMed ID: 22971245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody.
    Peng S; Ferrall L; Gaillard S; Wang C; Chi WY; Huang CH; Roden RBS; Wu TC; Chang YN; Hung CF
    mBio; 2021 Jan; 12(1):. PubMed ID: 33468698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
    Seo SH; Jin HT; Park SH; Youn JI; Sung YC
    Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical development of highly effective and safe DNA vaccines directed against HPV 16 E6 and E7.
    Oosterhuis K; Ohlschläger P; van den Berg JH; Toebes M; Gomez R; Schumacher TN; Haanen JB
    Int J Cancer; 2011 Jul; 129(2):397-406. PubMed ID: 21207427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA vaccine encoding heat shock protein 60 co-linked to HPV16 E6 and E7 tumor antigens generates more potent immunotherapeutic effects than respective E6 or E7 tumor antigens.
    Huang CY; Chen CA; Lee CN; Chang MC; Su YN; Lin YC; Hsieh CY; Cheng WF
    Gynecol Oncol; 2007 Dec; 107(3):404-12. PubMed ID: 17905417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel "priming-boosting" strategy for immune interventions in cervical cancer.
    Liao S; Zhang W; Hu X; Wang W; Deng D; Wang H; Wang C; Zhou J; Wang S; Zhang H; Ma D
    Mol Immunol; 2015 Apr; 64(2):295-305. PubMed ID: 25575128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination of full-length HPV16 E6 or E7 protein inhibits the growth of HPV16 associated tumors.
    Li YL; Qiu XH; Shen C; Liu JN; Zhang J
    Oncol Rep; 2010 Nov; 24(5):1323-9. PubMed ID: 20878127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel therapeutic vaccine composed of a rearranged human papillomavirus type 16 E6/E7 fusion protein and Fms-like tyrosine kinase-3 ligand induces CD8
    Li J; Chen S; Ge J; Lu F; Ren S; Zhao Z; Pu X; Chen X; Sun J; Gu Y
    Vaccine; 2017 Nov; 35(47):6459-6467. PubMed ID: 29029939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel self-assembled nanoparticle vaccine with HIV-1 Tat₄₉₋₅₇/HPV16 E7₄₉₋₅₇ fusion peptide and GM-CSF DNA elicits potent and prolonged CD8⁺ T cell-dependent anti-tumor immunity in mice.
    Tang J; Yin R; Tian Y; Huang Z; Shi J; Fu X; Wang L; Wu Y; Hao F; Ni B
    Vaccine; 2012 Feb; 30(6):1071-82. PubMed ID: 22178528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B surface antigen fusions delivered by DNA vaccination elicit CTL responses to human papillomavirus oncoproteins associated with tumor protection.
    Haigh O; Kattenbelt J; Cochrane M; Thomson S; Gould A; Tindle R
    Cancer Gene Ther; 2010 Oct; 17(10):708-20. PubMed ID: 20539319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and evaluation of a multi-epitope DNA vaccine against HPV16.
    Zhu L; Cui X; Yan Z; Tao Y; Shi L; Zhang X; Yao Y; Shi L
    Hum Vaccin Immunother; 2024 Dec; 20(1):2352908. PubMed ID: 38780076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antigen design enhances the immunogenicity of Semliki Forest virus-based therapeutic human papillomavirus vaccines.
    Ip PP; Boerma A; Walczak M; Oosterhuis K; Haanen JB; Schumacher TN; Nijman HW; Daemen T
    Gene Ther; 2015 Jul; 22(7):560-7. PubMed ID: 25756550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-tumor DNA vaccines based on the expression of human papillomavirus-16 E6/E7 oncoproteins genetically fused with the glycoprotein D from herpes simplex virus-1.
    Lasaro MO; Diniz MO; Reyes-Sandoval A; Ertl HC; Ferreira LC
    Microbes Infect; 2005 Dec; 7(15):1541-50. PubMed ID: 16213178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
    Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
    Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of antitumour protective cytotoxic T lymphocyte responses to a human papillomavirus 16 E7 DNA vaccine by coinjection of interleukin-12 complementary DNA: involvement of nitric oxide in immune suppression.
    Sin JI
    Immunology; 2009 Sep; 128(1 Suppl):e707-17. PubMed ID: 19740332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fusion protein vaccines targeting two tumor antigens generate synergistic anti-tumor effects.
    Cheng WF; Chang MC; Sun WZ; Jen YW; Liao CW; Chen YY; Chen CA
    PLoS One; 2013; 8(9):e71216. PubMed ID: 24058440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA vaccine against human papillomavirus type 16: modifications of the E6 oncogene.
    Poláková I; Pokorná D; Dusková M; Smahel M
    Vaccine; 2010 Feb; 28(6):1506-13. PubMed ID: 20003917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design of a highly effective therapeutic HPV16 E6/E7-specific DNA vaccine: optimization by different ways of sequence rearrangements (shuffling).
    Almajhdi FN; Senger T; Amer HM; Gissmann L; Öhlschläger P
    PLoS One; 2014; 9(11):e113461. PubMed ID: 25422946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA vaccine encoding HPV-16 E7 with mutation in L-Y-C-Y-E pRb-binding motif induces potent anti-tumor responses in mice.
    Bahrami AA; Ghaemi A; Tabarraei A; Sajadian A; Gorji A; Soleimanjahi H
    J Virol Methods; 2014 Sep; 206():12-8. PubMed ID: 24880067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth.
    Esquerré M; Momot M; Goubier A; Gonindard C; Leung-Theung-Long S; Misseri Y; Bissery MC
    Vaccine; 2017 Mar; 35(11):1509-1516. PubMed ID: 28196735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.